Glooko touted data today from a six-month pilot program that evaluated the company’s remote diabetes management technology for people with Type II diabetes.
The pilot, which spanned from April until October of 2016, involved 50 Type II diabetes patients from San Diego, Calif.-based Sharp Rees-Stealy Medical Group. The medical group evaluated patient engagement, A1c levels, LDL, microalbumin and blood pressure throughout the course of the study.
Get the full story at our sister site, Drug Delivery Business News.
The post Glooko touts patient outcomes for remote diabetes care tech appeared first on MassDevice.